Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.69+0.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · REPL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks REPL against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 instit…
Stated in 1 of 3 supplied quarters. Management reported: “Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.” “The Company has actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable TUDRIQEV adoption.”
“Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 instit…”
The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician's choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or ar…
Stated in 2 of 3 supplied quarters. Management reported: “The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician's choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment is actively enrolling.” “The trial is evaluating RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab.”
[/TABLE] We expect that our existing cash and cash equivalents will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, w…
Stated in 2 of 3 supplied quarters. Management reported: “The increase in cash balance was a result of approximately net $141.0 million in proceeds from the Company's offering of common stock and pre-funded warrants in August 2026, as well as $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026, partially offset by cash burn related to operating activities in advancing the company’s clinical development plans.” “This decrease was primarily due to a decrease in personnel related and other costs, as well as a decrease in direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies.”
Commercialize TUDRIQEV for advanced melanoma by building launch infrastructure, reaching priority accounts, and supporting adoption.
Work with the FDA through the RP1 application process and pursue access to RP1, now marketed as TUDRIQEV, for advanced melanoma.
Over the trailing year it converted 0.96x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.
“The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician's choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or ar…”
“The primary endpoint of this trial is overall survival, and key secondary endpoints are progression free survival and overall response rate.”
“[/TABLE] We expect that our existing cash and cash equivalents will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, w…”
“[TABLE] • | R&D Expenses: Research and development expenses were $52.3 million for the fiscal fourth quarter and $221.2 million for the fiscal year ended March 31, 2026 , as compared to $54.0 million…”